Andrea Bernardos

Universitat de València — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.7kcitations85works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced biosensing and bioanalysis techniques(13), Mesoporous Materials and Catalysis(13), Essential Oils and Antimicrobial Activity(9), Nanoparticle-Based Drug Delivery(6), Luminescence and Fluorescent Materials(6)

Publications85 total

Table S7 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S9 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S3 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S8 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Data from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S5 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Table S10 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Supplementary Figure 5 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025Open Access
Chemical screening and biological activity of various species of wood-decay fungi of the genus Ganoderma
Phytochemistry Letters·2025
Chitosan nanoparticles-encapsulated cannabis extracts and their antimicrobial potential against skin pathogens
Frontiers in Medicine·2025Open Access
Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
Molecular Cancer Therapeutics·2025· 5 cited
page 1 of 5Next →

Frequent Co-authors

Ramón Martínez‐Máñez(46), Félix Sancenón(26), M. Dolores Marcos(22), José Manuel Barat Baviera(14), Elena Aznar(11), Pedro Amorós(9), Édgar Pérez‐Esteve(9), Juán Soto(8), Beatriz Lozano‐Torres(6), Laura Mondragón(6), Ana M. Costero(5), Pavel Klouček(5), Irene Galiana(4), José Ramón Murguía(4), Manuel Serrano(4), Carmen Coll(4), María Ruiz‐Rico(4), Adéla Fraňková(4), Miloslav Lhotka(4), Elisa Poyatos‐Racionero(4)